Genetic variation in cell cycle and apoptosis related genes and multiple myeloma risk

Leukemia Research

Volumn 33, Issue 12, 2009, Pages 1609-1614

  Hosgood III, H Dean ^a   Baris, Dalsu ^a   Zhang, Yawei ^b   Berndt, Sonja I ^a   Menashe, Idan ^a   Morton, Lindsay M ^a   Lee, Kyoung Mu ^a   Yeager, Meredith ^a   Zahm, Shelia H ^a   Chanock, Stephen ^a   Zheng, Tongzhang ^b   Lan, Qing ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

BAX; Caspase; Cell cycle; Multiple myeloma; RIPK1

Indexed keywords

CASPASE 9; PROTEIN BAX; RECEPTOR INTERACTING PROTEIN SERINE THREONINE KINASE;

ADULT; AGED; APOPTOSIS; ARTICLE; CANCER RISK; CELL CYCLE; CONTROLLED STUDY; FEMALE; GENETIC ASSOCIATION; GENETIC VARIABILITY; HAPLOTYPE; HUMAN; MAJOR CLINICAL STUDY; MULTIPLE MYELOMA; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM;

AGED; APOPTOSIS; CASE-CONTROL STUDIES; CELL CYCLE; FEMALE; GENETIC VARIATION; HUMANS; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 70349170571     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2009.03.013     Document Type: Article

References (38)

1. Jemal A., Siegel R., Ward E., Murray T., Xu J., and Thun M.J. Cancer statistics, 2007. CA Cancer J Clin 57 January (1) (2007) 43-66
2. Hideshima T., Mitsiades C., Tonon G., Richardson P.G., and Anderson K.C. Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets. Nat Rev Cancer 7 August (8) (2007) 585-598
3. Adams J.M., and Cory S. The Bcl-2 protein family: arbiters of cell survival. Science 281 August (5381) (1998) 1322-1326
4. Hajra K.M., and Liu J.R. Apoptosome dysfunction in human cancer. Apoptosis 9 November (6) (2004) 691-704
5. Nicholson D.W., and Thornberry N.A. Caspases: killer proteases. Trends Biochem Sci 22 August (8) (1997) 299-306
6. De Roos A., Baris D., Weiss N., Herrinton L., and Multiple myeloma. In: Schottenfeld D., and Fraumeni J.F. (Eds). Cancer epidemiology and prevention. 3rd ed. (2006), Oxford University Press, New York
7. Alexander D.D., Mink P.J., Adami H.O., Cole P., Mandel J.S., Oken M.M., et al. Multiple myeloma: a review of the epidemiologic literature. Int J Cancer 120 Suppl. 12 (2007) 40-61
8. Landgren O., Linet M.S., McMaster M.L., Gridley G., Hemminki K., and Goldin L.R. Familial characteristics of autoimmune and hematologic disorders in 8,406 multiple myeloma patients: a population-based case-control study. Int J Cancer 118 June (12) (2006) 3095-3098
9. Hemminki K., Li X., and Czene K. Familial risk of cancer: data for clinical counseling and cancer genetics. Int J Cancer 108 January (1) (2004) 109-114
10. Zheng C., Huang D., Liu L., Bjorkholm M., Holm G., Yi Q., et al. Cytotoxic T-lymphocyte antigen-4 microsatellite polymorphism is associated with multiple myeloma. Br J Haematol 112 January (1) (2001) 216-218
11. Zheng C., Huang D., Liu L., Wu R., Bergenbrant G.S., Osterborg A., et al. Interleukin-10 gene promoter polymorphisms in multiple myeloma. Int J Cancer 95 May (3) (2001) 184-188
12. Brown E.E., Lan Q., Zheng T., Zhang Y., Wang S.S., Hoar-Zahm S., et al. Common variants in genes that mediate immunity and risk of multiple myeloma. Int J Cancer 120 12 (2007) 2715-2722
13. Lincz L.F., Kerridge I., Scorgie F.E., Bailey M., Enno A., and Spencer A. Xenobiotic gene polymorphisms and susceptibility to multiple myeloma. Haematologica 89 May (5) (2004) 628-629
14. Kang S.H., Kim T.Y., Kim H.Y., Yoon J.H., Cho H.I., Yoon S.S., et al. Protective role of CYP1A1*2A in the development of multiple myeloma. Acta Haematol 119 1 (2008) 60-64
15. Ortega M.M., Nascimento H., Melo M.B., Teori M.T., Costa F.F., and Lima C.S. Polymorphisms of glutathione S-transferase mu1 (GSTM1) and theta1 (GSTT1) genes in multiple myeloma. Acta Haematol 109 2 (2003) 108-109
16. Velangi M.R., Matheson E.C., Morgan G.J., Jackson G.H., Taylor P.R., Hall A.G., et al. DNA mismatch repair pathway defects in the pathogenesis and evolution of myeloma. Carcinogenesis 25 October (10) (2004) 1795-1803
17. Hayden P.J., Tewari P., Morris D.W., Staines A., Crowley D., Nieters A., et al. Variation in DNA repair genes XRCC3, XRCC4, XRCC5 and susceptibility to myeloma. Hum Mol Genet 16 December (24) (2007) 3117-3127
18. Hosgood III H.D., Baris D., Zhang Y., Zhu Y., Zheng T., Yeager M., et al. Caspase polymorphisms and genetic susceptibility to multiple myeloma. Hematol Oncol 26 3 (2008) 148-151
19. Garcia-Closas M., Egan K.M., Abruzzo J., Newcomb P.A., Titus-Ernstoff L., Franklin T., et al. Collection of genomic DNA from adults in epidemiological studies by buccal cytobrush and mouthwash. Cancer Epidemiol Biomarkers Prev 10 June (6) (2001) 687-696
20. Carlson C.S., Eberle M.A., Rieder M.J., Yi Q., Kruglyak L., and Nickerson D.A. Selecting a maximally informative set of single-nucleotide polymorphisms for association analyses using linkage disequilibrium. Am J Hum Genet 74 January (1) (2004) 106-120
21. Chen B.E., Sakoda L.C., Hsing A.W., and Rosenberg P.S. Resampling-based multiple hypothesis testing procedures for genetic case-control association studies. Genet Epidemiol 30 September (6) (2006) 495-507
22. Excoffier L., and Slatkin M. Maximum-likelihood estimation of molecular haplotype frequencies in a diploid population. Mol Biol Evol 12 September (5) (1995) 921-927
23. Schaid D.J., Rowland C.M., Tines D.E., Jacobson R.M., and Poland G.A. Score tests for association between traits and haplotypes when linkage phase is ambiguous. Am J Hum Genet 70 February (2) (2002) 425-434
24. Shivapurkar N., Reddy J., Chaudhary P.M., and Gazdar A.F. Apoptosis and lung cancer: a review. J Cell Biochem 88 April (5) (2003) 885-898
25. Lan Q., Zheng T., Chanock S., Zhang Y., Shen M., Wang S.S., et al. Genetic variants in caspase genes and susceptibility to non-Hodgkin lymphoma. Carcinogenesis 28 4 (2007) 823-827
26. Helmbrecht K., Zeise E., and Rensing L. Chaperones in cell cycle regulation and mitogenic signal transduction: a review. Cell Prolif 33 December (6) (2000) 341-365
27. Mitra A., Fillmore R.A., Metge B.J., Rajesh M., Xi Y., King J., et al. Large isoform of MRJ (DNAJB6) reduces malignant activity of breast cancer. Breast Cancer Res 10 March (2) (2008) R22
28. Lindsey J.C., Lusher M.E., Strathdee G., Brown R., Gilbertson R.J., Bailey S., et al. Epigenetic inactivation of MCJ (DNAJD1) in malignant paediatric brain tumours. Int J Cancer 118 January (2) (2006) 346-352
29. Starczynski J., Pepper C., Pratt G., Hooper L., Thomas A., Milligan D., et al. Common polymorphism G(-248)A in the promoter region of the bax gene results in significantly shorter survival in patients with chronic lymphocytic Leukemia once treatment is initiated. J Clin Oncol 23 March (7) (2005) 1514-1521
30. Skogsberg S., Tobin G., Krober A., Kienle D., Thunberg U., Aleskog A., et al. The G(-248)A polymorphism in the promoter region of the Bax gene does not correlate with prognostic markers or overall survival in chronic lymphocytic leukemia. Leukemia 20 January (1) (2006) 77-81
31. Wojcik I., Szybka M., Golanska E., Rieske P., Blonski J.Z., Robak T., et al. Abnormalities of the P53, MDM2, BCL2 and BAX genes in acute leukemias. Neoplasma 52 4 (2005) 318-324
32. Meylan E., and Tschopp J. The RIP kinases: crucial integrators of cellular stress. Trends Biochem Sci 30 March (3) (2005) 151-159
33. Devin A., Cook A., Lin Y., Rodriguez Y., Kelliher M., and Liu Z. The distinct roles of TRAF2 and RIP in IKK activation by TNF-R1: TRAF2 recruits IKK to TNF-R1 while RIP mediates IKK activation. Immunity 12 April (4) (2000) 419-429
34. Morgan G.J., Adamson P.J., Mensah F.K., Spink C.F., Law G.R., Keen L.J., et al. Haplotypes in the tumour necrosis factor region and myeloma. Br J Haematol 129 May (3) (2005) 358-365
35. Zheng C., Huang D.R., Bergenbrant S., Sundblad A., Osterborg A., Bjorkholm M., et al. Interleukin 6, tumour necrosis factor alpha, interleukin 1beta and interleukin 1 receptor antagonist promoter or coding gene polymorphisms in multiple myeloma. Br J Haematol 109 April (1) (2000) 39-45
36. Brown E.E., Lan Q., Zheng T., Zhang Y., Wang S.S., Hoar-Zahm S., et al. Common variants in genes that mediate immunity and risk of multiple myeloma. Int J Cancer 120 June (12) (2007) 2715-2722
37. Wacholder S., Chanock S., Garcia-Closas M., El G.L., and Rothman N. Assessing the probability that a positive report is false: an approach for molecular epidemiology studies. J Natl Cancer Inst 96 March (6) (2004) 434-442
38. Bhatti P., Sigurdson A.J., Wang S.S., Chen J., Rothman N., Hartge P., et al. Genetic variation and willingness to participate in epidemiologic research: data from three studies. Cancer Epidemiol Biomarkers Prev 14 October (10) (2005) 2449-2453